EMILY HECKMAN: Open Payments
NPI 1902327927 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,443 in 83 payments from 22 companies in 2025. Trend: 2023 $1,445 · 2024 $1,820 · 2025 $1,443
Food & beverage: $1,443
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $477 |
| Novo Nordisk Inc | 11 | $182 |
| AstraZeneca Pharmaceuticals LP | 6 | $147 |
| Abbott Laboratories | 5 | $87 |
| Amgen Inc. | 4 | $68 |
| Lilly USA, LLC | 3 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $50 |
| Amneal Pharmaceuticals LLC | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $37 |
Products named: QULIPTA, UBRELVY, VRAYLAR, AIRSUPRA, Rybelsus, OTEZLA, FREESTYLE LIBRE 3, CAPLYTA.
Industry payments across PA — which companies pay providers there.
